Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KEIB047
- Development stage
- Unknown
- Lead developer
- Kibow Biotech
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
KEIB047 is a probiotic formulation, classified as a live biotherapeutic product (LBP), currently under clinical investigation as an adjuvant therapy for mild-to-moderate ulcerative colitis. Developed by researchers at The First Affiliated Hospital of Nanchang University, the agent is typically administered orally in conjunction with standard-of-care mesalazine. The therapeutic rationale for KEIB047 involves the modulation of the gut microbiota to restore microbial diversity, the enhancement of intestinal epithelial barrier function, and the reduction of mucosal pro-inflammatory signaling. By stabilizing the intestinal environment, KEIB047 aims to improve clinical remission rates and mucosal healing in patients who are inadequately controlled by aminosalicylates alone.
- Other names
- KEIB047 probioticsKEIB-047 probioticsKEIB 047 probiotics
Beyond the preview
Go deeper on KEIB047.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KEIB047.